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Abstract. Cutaneous melanoma (CM) is the most aggres‑
sive form of skin cancer, exhibits an increasing incidence 
worldwide and has a high potential to develop metastasis. The 
current study aimed to identify a set of parameters that may 
aid in predicting the probability and timing of the onset of CM 
metastasis. A retrospective analysis was performed using the 
archive data of 2,026 patients with CM that were treated at the 
Riga East University Hospital Latvian Oncology Centre, which 
is the largest oncological hospital in the country, between 1998 
and 2015. A case‑control study design was employed, where 
patients with metastasis (n=278) were used as the cases and 
patients without metastasis were used as the controls. The 
present study examined the associations between metastasis 
and potential risk factors and constructed multivariate models 
of features that predicted metastasis using stepwise regression. 
Time until metastasis was analyzed using negative binomial 
regression models. The results of the present study indicated 
an increase in the number of melanomas that developed 
metastases during 1998‑2015. Tumor Breslow thickness was 
demonstrated to be significantly larger in patients with metas‑
tasis compared with those without (P=0.012). The presence 
of ulceration significantly increased the risk of metastases 
[odds ratio (OR), 1.66; 95% CI, 1.07‑2.59; P=0.033]. The 
absence of pigment in melanoma tissues was indicated to 
lead to a greater likelihood of metastasis (OR, 2.14; 95% CI, 
1.10‑4.19; P=0.035). Shorter times from diagnosis until the 
onset of metastases were observed in older patients (incident 
rate ratio (IRR), 6.85; 95% CI, 2.43‑19.30; P=2.78x10‑4), and a 
borderline significant association was observed in those with 
ulcerated tumors (IRR, 1.33; 95% CI, 0.98‑1.80; P=0.064). 
Therefore, the main features associated with the development 
of melanoma metastasis in Latvia were indicated to be tumor 
ulceration, absence of pigment and Breslow thickness.
Introduction
Cutaneous melanoma (CM) is one of the most aggressive types 
of skin cancer and mainly affects the Caucasian population (1). 
Epidemiological data collected across the world demonstrate a 
steady increase in the incidence of melanoma in recent decades. 
In the USA, the incidence of CM in the Caucasian subpopulation 
increased from 20.9 in 1996 to 31.5 in 2017 (2) (the incidence 
rates reported are per 100,000 individuals per year). In Germany, 
the incidence of CM grew from 10.3 in 1976 to 13.3 in 2003 (3). 
In Finland, from 1953‑2003 the incidence of CM changed 
from 1.5 to 12.8 (4). The incidence of melanoma in Latvia has 
increased from 5.1 new melanoma cases per 100,000 inhabit‑
ants in 1998 to 7.8 in 2008 (5). Although this increase is mainly 
attributed to the early detection of the disease, the number of 
patients diagnosed with advanced melanoma and with cancer 
exhibiting metastatic potential is also growing worldwide (6,7), 
with ~30% of patients with primary melanoma developing 
metastasis (8,9). Metastatic melanoma has a poor prognosis, 
with the median survival time ranging between 8 and 18 months 
following diagnosis depending on the tumor stage (10,11). The 
efficacy of the treatment of metastatic melanoma in recent years 
has increased following the successful application of small 
molecular inhibitors that target specific oncogenic mutations, for 
example those within the BRAF gene (12,13). Studies have also 
suggested that the development of immunotherapy with check‑
point inhibitors, which involves using monoclonal antibodies 
to cytotoxic T lymphocyte antigen‑4 and programmed death‑1 
receptor/ligand, may aid in the treatment of this disease (14‑16). 
However, the efficacy of these treatments is limited by the devel‑
opment of resistance to targeted therapy (12,13). Furthermore, 
durable response to immunotherapy is restricted only to a subset 
of patients (14‑16).
The previously reported risk factors for a poor outcome 
of melanoma include high Breslow thickness, ulceration, high 
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mitotic rate, high levels of lactate dehydrogenase, lymphovas‑
cular invasion and microscopic and clinical satellites (17‑22). 
The formation of metastasis has also been associated with old 
age, the presence of a number of primary tumor localizations 
and a history of skin cancer or other types of cancer (23‑25). In 
the aforementioned studies, the majority of melanomas were 
thin and rarely exceeded a Breslow thickness of 4.0 mm; by 
contrast, melanomas in Latvia have been reported to exhibit a 
median thickness of 6.0 mm (5). This may be due to the delays 
in seeking medical assistance, which allows for a unique 
patient cohort where patients with metastasis are well repre‑
sented and the tumors exhibit diverse features. This cohort 
presents opportunities for identifying additional features that 
may be associated with melanoma metastasis. In addition, to 
the best of our knowledge, the current study is the first system‑
atic study of metastatic melanoma in the Latvian population. 
The aim of the present study was to analyze patient data and 
tumor characteristics in order to identify a set of parameters 
that may aid in predicting the probability and timing of the 
onset of CM metastasis.
Materials and methods
Design and data sources. In the present retrospective case‑control 
analysis, patients with metastasis (T stages IIIA‑IV) served as the 
cases (the first occurrence of metastasis for the primary tumor 
was considered), whereas patients with melanoma who did not 
develop metastasis during the study period were used as the 
controls (T stages IA‑IIC). Staging was determined according 
to the guidelines by the American Joint Committee of Cancer, 
8th Edition (11). Patient inclusion criteria were: Histologically 
confirmed melanoma with metastasis (corresponding to the 
T stage groups IIIA‑IV) for cases and histologically confirmed 
melanoma without metastasis (corresponding to the T stage 
groups IA‑IIC) for controls. Patients with multiple primary 
melanomas where it was not possible to identify a single original 
melanoma were excluded from the study. The cases and controls 
were selected from a cohort of 2,026 patients with CM that were 
treated at the Riga East University Hospital Latvian Oncology 
Centre (REUHLOC), which is the largest oncological hospital 
in Latvia, between January 1998 and December 2015. Of all 
melanoma cases in Latvia, ~80% were referred to REUHLOC 
during this time period. Metastasis was defined as in‑transit 
metastasis (manifested before regional lymph nodes), metastasis 
with regional lymph node involvement or distant metastasis. 
A total of 647 patients in the cohort developed metastasis. 
Individuals for whom metastasis was detected at the time of the 
diagnosis of primary tumor or <6 months after the initial diag‑
nosis were excluded from the analysis due to a high probability 
of exhibiting metastasis in a subclinical form at the time of the 
diagnosis. Following this exclusion, 309 cases remained and 
were used for subsequent analysis. For each case, one control 
initially diagnosed in the same year was selected; the chosen 
control patient was required to have been followed up at least 
until the time when metastasis had been detected in the case 
patient and not to have died prior to the diagnosis of metastases. 
Age and sex were also considered when matching a case patient 
with a control: Patients were divided into age groups spanning 
20 years each, and each patient was matched with a control from 
the same age group and of the same sex. When several controls 
were available, one control was selected at random. A total of 
278 cases were successfully matched using all the criteria, and 
the total number of individuals included in the case‑control 
study was 556. The variables examined for an association with 
the risk of developing metastasis were body mass index (BMI) 
and tumor characteristics, including CM subtype, predominant 
cell type in the lesion, Breslow thickness, presence of ulcer‑
ation, pigment and anatomic localization of the tumor. Tumor 
localizations were grouped into the following regions: Head 
and neck, limbs, hands and feet, and trunk. Among the CM 
subtypes, superficial spreading melanoma, nodular melanoma 
and lentigo malignant melanoma were distinguished. Of all 
predominant cell types, epithelial, spindle and mixed cell types 
were discerned.
Statistical analysis. The associations between potential risk 
factors (categorical features) and the probability of devel‑
oping metastasis were assessed using a Pearson's χ2 test. The 
distributions of risk factors for male and female patients were 
compared in the same way for case and control groups. If 
the number of patients in one of the subgroups was small, a 
Fisher's exact test was used. If the association with a factor was 
significant and the factor had ≥3 discrete categories, pairwise 
comparisons between the categories were performed using 
Fisher's exact test. The differences in Breslow thickness, age 
and BMI (continuous features) were also assessed using the 
non‑parametric Mann‑Whitney test. For continuous features 
the mean ± standard deviation (mean ± SD) was reported. Both 
Pearson's χ2 tests and Fisher's exact tests were carried out using 
R software version 3.6.3. (functions ‘chisq.test’ and ‘fisher.
test’ were used, respectively) (26). Odds ratios were calculated 
using the R function ‘oddsratio’. Mann‑Whitney test P‑values 
were obtained by the ‘wilcox.test’ in R. P<0.05 was considered 
to indicate a statistically significant difference.
Multivariate models were constructed using several risk 
factors associated with the presence or absence of metastases. 
Logistic regression models were used in all multivariate 
analyses. Multivariate models were constructed using stepwise 
regression, where the candidate variables were Breslow thick‑
ness, BMI (both analyzed as continuous variables), ulceration, 
pigment and tumor localization. Multivariate models included 
patients with no missing data for the analyzed variables 
(n=272; 136 cases and controls matched for sex and age). 
CM subtype and predominant cell type in the lesion were not 
included in the present analysis due to insignificant P‑values 
in the univariate analysis (Pearson's χ2 test or Fisher's exact 
test P‑values were regarded as appropriate for the number of 
observations; the test that involved all categories of a feature 
was referred to) and missing observations. Models were built 
using the function ‘stepAIC’ from the R package ‘MASS’, 
starting with a model without any factors (27).
Within the group of patients with metastasis (n=309), time 
from initial diagnosis until the diagnosis of metastasis was 
compared for a variety of subgroups. The features that were 
previously considered for the inclusion in the multivariate 
models were analyzed. A negative binomial regression model 
was fitted for each risk factor. The R function ‘glm.nb’ was 
used for computations.
Patient survival was assessed using the Cox proportional 
hazards model. The significance of the association between 
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metastasis and survival was examined using the log‑rank 
test, which was applied to the model. The R function ‘coxph’ 
from the package ‘survival’ was used for the analysis (28). 
Kaplan‑Meier curves were analyzed using the function ‘survfit’ 
and were visualized using the R package ‘ggfortify’ (29,30). 
To compare the estimated survival of the present study with 
already published data the Surveillance, Epidemiology and 
End Results (SEER) database (2) was used for the Caucasian 
population.
Results
Patient characteristics. The number of newly diagnosed 
cases of metastasis was demonstrated to consistently increase 
over time in the study cohort (Fig. 1A). A total of 647 out of 
2,026 patients (31.9%) were indicated to develop metastasis, 
and 219 (10.8%) patients presented with metastasis at the 
time of diagnosis. A total of 428 (21.1%) patients developed 
metastasis during the study period, and of these, 119 patients 
(5.9%) developed metastases within the first 6 months 
following treatment and were subsequently excluded from 
the case‑control study. Therefore, a total of 309 patients with 
melanoma (15.3%), for which metastases were diagnosed at 
≥6 months after the beginning of treatment, were included in 
the analysis. Of these, 278 patients were matched with controls 
by age and sex, including 164 female (59.0%) and 114 male 
(41.0%) patients. The mean age was 61.8±14.9 years for female 
and 61.1±13.6 years for male patients (Mann‑Whitney test, 
P=0.340). The majority of the patients (n=192 or 66.7%) devel‑
oped metastasis within the first two years following surgery 
(Fig. 1B).
Risk factors associated with melanoma metastasis. The 
distribution of risk factors within the case and control groups, 
and the associations between clinicopathological features 
and metastasis are presented in Table I. Thick melanomas 
were observed in the case and control groups, although the 
mean tumor thickness at diagnosis was higher in patients 
with metastasis compared with that in patients without 
metastasis (5.21 vs. 4.02 mm, respectively; Mann‑Whitney 
test, P=0.012). The likelihood of developing metastasis for 
patients with melanoma Breslow thickness >4.00 mm and 
those with lower Breslow thickness was also compared, as 
4.00 mm is the threshold used for separating patients with 
melanoma T stages IA‑IIC and stages IIIA‑IV; the likelihood 
of metastasis was significantly higher in patients with mela‑
noma Breslow thickness >4.00 mm [odds ratio (OR), 1.59; 
95% CI, 1.06‑2.38; P=0.030]. Pairwise comparisons among 
four intervals of Breslow thickness indicated that patients 
with melanomas with Breslow thickness 2.01‑4.00 and >4 mm 
were more likely to develop metastasis compared with patients 
with melanomas of 1.01‑2.00 mm (P=0.009 and P=4.94x10‑4, 
respectively; Table SI). The presence of ulceration significantly 
increased the risk of metastasis (OR, 1.66; 95% CI, 1.07‑2.59; 
P=0.033), and the absence of pigment from melanoma tissue 
was also associated with the likelihood of metastasis (OR, 
2.14; 95% CI, 1.10‑4.19; P=0.035; Table I).
Within the initial cohort of 309 individuals, which were 
paired with controls only by the year of initial diagnosis and 
the time of follow‑up, male sex also appeared to be a signifi‑
cant risk factor (OR, 1.53; 95% CI, 1.10‑2.12; P=0.013). In 
addition, the anatomical localization of melanoma was associ‑
ated with the development of metastasis (P=0.034; Table SII). 
To explore this further, the differences in melanoma features 
between female and male patients were examined. The 
anatomical localization of melanoma was the only character‑
istic that was indicated to be significantly different for male 
and female patients (Table II). Localizations differed for both 
sexes among the patients with metastasis (P=0.010) as well 
as among the control subjects without metastasis (P=0.003; 
Table SIII). Relative to those on limbs, male patients presented 
with more cases of melanoma on their trunk, hands and 
feet, as well as on the head and neck compared with female 
patients (Table III). Melanoma localization on the trunk had 
significantly different frequencies for males and females when 
individuals were stratified into groups by metastatic status, 
Figure 1. Occurrence of metastasis in the cohort. (A) The number of newly diagnosed metastases by year. (B) Time to metastasis in years from primary 
diagnosis.
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and it differed by sex for patients without and with metastasis 
(OR, 2.82; 95% CI, 1.61‑4.96; P=3.26x10‑4; and OR, 2.47; 
95% CI, 1.43‑4.25; P=1.22x10‑3, respectively; Tables SIV and 
SV). The analysis of melanoma features within the female 
and male cohorts separately demonstrated that tumor Breslow 
thickness, ulceration and absence of pigment were associated 
Table I. Risk factors for melanoma metastasis (sex‑ and age‑matched dataset, n=278).
 Patients with Patients without
 metastasis metastasis
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Risk factor N % N % OR (95% CI) P‑valuea
Tumor localization      
  Head and neck   28 10.1   41   14.7  0.400
  Limbs 113 40.6 104   37.4  
  Trunk 117 42.1 115   41.4  
  Hands and feetd   20 7.2   18     6.5  
  Totale 278 100.0 278 100.0  
CM subtype      
  Superficial spreading melanoma   15 20.8     8   11.1  0.219c
  Nodular melanoma   55 76.4   60   83.3  
  Lentigo malignant melanoma     2 2.8     4     5.6  
  Totale   72 100.0   72 100.0  
Breslow thickness, mm     
  Mean ± SD 5.21±6.17 4.02±4.95 0.012b
  Median  4.0 2.5 
  ≤1.0   54 25.1   55   25.5  0.005
  1.0‑2.0   23 10.7   49   22.8  
  2.0‑4.0   55 25.6   50   23.3  
  >4.0   83 38.6   61   28.4  
  Totale 215 100.0 215 100.0  
Ulceration     
  Absent   61 37.9   81   50.3 Reference 
     1.66 (1.07‑2.59)
  Present 100 62.1   80   49.7  0.033
  Totale 161 100.0 161 100.0  
Pigment     
  Present 195 87.4 209   93.7 Reference 
     2.14 (1.10‑4.19)
  Absent   28 12.6   14     6.3  0.035
  Totale 223 100.0 223 100.0  
Predominant cell type in the lesion      
  Epithelial 121    67.6 118   65.9 0.139
  Spindle   21    11.7   33   18.4 
  Mixed   37    20.7   28   15.7 
  Totale 179  100.0 179 100.0 
BMI      
  Mean ± SD 28.64±5.56 28.20±5.93  0.462b
  Median 27.5 27.8  
  18.61‑25.00   40    27.0   44   29.7 0.869
  25.01‑30.00   57    38.5   54   36.5 
  >30.01   51    34.5   50   33.8 
  Totale 148  100.0 148 100.0 
aP‑values were obtained by the χ2 test unless indicated otherwise. bMann‑Whitney test. cFisher's exact test. dAcral lentiginous melanomas were 
excluded before analysis. eThe number of matched cases in each group; if there was missing information for an individual in one of the groups, 
the corresponding case‑control pair was excluded from the analysis. OR and 95% CI are presented for predictors with two categories. If a 
predictor had more than two categories, then the overall significance of a predictor was evaluated first. If the obtained P‑value was significant 
(e.g., Breslow thickness), pairwise comparisons were performed, and odds ratios were calculated for combinations of two categories (Table SI).
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with metastasis in female patients, whereas similar associa‑
tions were not observed in the male cohort (Table II).
Multivariate models built by stepwise regression demon‑
strated that the only independently significant prognostic 
factor for the development of metastasis was tumor ulceration, 
and it was selected as it significantly improved the multivariate 
model according to the overall model likelihood and the Akaike 
Information Criterion (ulceration OR, 1.62; 95% CI,1.00‑2.62; 
P=0.051). Age and sex were incorporated in this model by the 
matching of cases and controls.
Patient survival. The survival of patients exhibiting primary 
melanoma differed significantly from those who developed 
metastasis [hazard ratio (HR), 3.50; 95% CI, 2.72‑4.51; 
P<2.00x10‑16; Fig. 2A]. Improved survival was also observed 
in female compared with male patients (HR, 1.44; 95% CI, 
1.14‑1.81; P=1.94x10‑3). However, this difference was only 
observed in females without metastasis (HR, 1.86; 95% CI, 
1.20‑2.88; P=5.04x10‑3), and was not observed once metas‑
tasis had developed (HR, 1.05; 95% CI, 0.80‑1.37; P=0.744; 
Fig. 2B‑D). The comparison of patients' survival in the 
present study with the survival reported in the SEER data 
base (2) demonstrated that the 5‑year survival after the 
initial diagnosis was 61.1% in the cohort of the present study 
compared with 91.6% for the Caucasian population in the 
SEER database. These differences in survival were observed 
both for localized disease (controls without metastasis; 
T stages IA‑IIC) and for melanoma with metastasis (cases; 
T stages IIIA‑IV). The survival rates were 41.9% (controls) 
and 80.7% (cases) in the present study compared with 65 
and 98.3% in the SEER database for the respective groups 
(Table IV) (2).
Time until metastasis since primary diagnosis. The time until 
metastasis was diagnosed was also considered in the current 
study. The results demonstrated that increased age was associ‑
ated with shorter time until metastasis (incident rate ratio (IRR), 
6.85; 95% CI, 2.43‑19.30; P=2.78x10‑4) (Fig. 3A). In addition, 
ulceration indicated a borderline significant association with 
shorter time until metastasis (IRR=1.33, 95% CI=0.98‑1.80; 
P=0.064; Fig. 3B). None of the remaining factors exhibited an 
association with shorter time until metastasis, including tumor 
Breslow thickness and sex (P=0.997 and P=0.588, respec‑
tively; Fig. 3C and D).
Discussion
The present study revealed an ascending trend for the 
number of melanomas that progress towards metastasis from 
1988‑2015. This trend was consistent with the observations of 
other studies, where a decline in late‑stage melanomas was not 
observed, and a decrease in the mortality caused by melanoma 
was also not observed (1). The results of the current study indi‑
cated that tumor ulceration exhibited the strongest association 
with melanoma metastasis. Furthermore, tumor ulceration was 
indicated to be the only independently significant prognostic 
factor for the development of metastasis in the multivariate 
model. Tumor ulceration has been previously reported to be 
a prognostic factor for melanoma (17,18,21,22). In the present 
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time until the development of metastasis. Tumor Breslow 
thickness was another factor that exhibited a strong association 
with melanoma metastasis; this measurement is an important 
hallmark of melanoma progression, and it is recognized as one 
of the main prognostic factors on which the current clinical 
staging of melanoma is based (10,11). Patients in the cohort 
used in the present study exhibited thicker melanomas with a 
median Breslow thickness of 3.00 mm (4.00 mm in patients 




 Limbs Hands and feetb Trunk Head and neck
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
 Tumor OR  OR  OR  OR
 localization (95% CI) P‑valuea (95% CI) P‑valuea (95% CI) P‑valuea (95% CI) P‑valuea
Female Limbs   2.25 (1.12‑4.54) 0.036 2.63 (1.78‑3.89) <0.001 1.81 (1.03‑3.18) 0.039
 Hands and feetb     1.17 (0.59‑2.33) 0.727 0.81 (0.36‑1.79) 0.685
 Trunk       1.45 (0.84‑2.50) 0.217
 Head and neck        
aP‑values were obtained by Fisher's exact test. bAcral lentiginous melanomas were excluded before analysis.
Figure 2. Kaplan‑Meier curves of differences in survival based on clinicopathological characteristics. (A‑D) Kaplan‑Meier curves of (A) patients with primary 
melanoma (T stage IA‑IIC) compared with those with metastasis (T stage IIIA‑IV), (B) female and male patients irrespective of the presence of metastasis, 
(C) female and male patients without metastasis and (D) female and male patients with metastasis.
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with metastasis and 2.50 mm in those without) compared with 
other studies reporting a median thickness of 0.62 mm and a 
steady decrease of this metric (6,31). However, the percentage 
of patients with primary melanoma who developed metastasis 
was only slightly higher in the current study compared with 
the previous literature at 31.9% vs. 30.0%, respectively (8,9). 
In addition, Breslow thickness exhibited no impact on the 
time when metastasis was diagnosed within the present study. 
Tumor thickness may be a proxy of the stage of primary 
tumor advancement, and the spreading of melanoma may be 
independent of the thickness of primary tumor at the time of 
diagnosis. This may mean that tumor Breslow thickness is 
not the main determinant of the speed with which metastasis 
develops, and that other mechanisms are responsible for this 
spread. Alternatively, the lack of association between Breslow 
thickness and the time of metastasis development may be due 
to the different effects of the initial Breslow thickness on early 
and late metastasis. Of note, the survival rate in the present 
cohort was noticeably lower compared with that reported in the 
literature (2). This might be explained by the delays in seeking 
Table IV. Patient 5‑year survival rates in the local cohort and the SEER database (2).
 5‑year survival rate, %
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Stage Local cohort SEER database
All melanomas 61.1 91.6
Localized disease (T stage IA‑IIC) 80.7 98.3
Metastasis (regional and distant; T stage IIIA‑IV) 41.9 65.0
SEER, Surveillance, Epidemiology and End Results.
Figure 3. Associations between time to metastasis in years and various characteristics of melanoma. (A‑D) Time to metastasis in years by (A) age at the time 
of diagnosis, (B) presence of ulceration, (C) logarithm of Breslow thickness (analyzed as a continuous variable) and (D) sex.
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medical assistance and by the availability of state‑of‑the‑art 
treatment options during the study period (1998‑2015) in 
Latvia. In addition patients' age and mortality from other 
diseases may have had an influence on this discrepancy, 
especially because the difference was similar for patients with 
metastasis and patients without metastasis (localized disease). 
This observation emphasizes the requirement for identifying 
additional patient and melanoma characteristics that may be 
associated with disease progression.
Ulceration, tumor Breslow thickness and the absence of 
pigment in melanoma tissues are known prognostic factors for 
melanoma (17,21) and were associated with metastasis in the 
cohort used in the present study. These features were associ‑
ated with the development of melanoma metastasis in female 
patients, whereas similar associations were not observed in the 
male cohort. However, male sex appeared to be a significant risk 
factor for the development of melanoma metastasis. In 1969, 
Clark et al (32) observed that melanomas were more aggressive in 
male patients compared with those in female patients. Numerous 
studies have consistently indicated sex to be an independent 
prognostic factor for the development of melanoma even after 
the adjustment for age, Breslow thickness, histological subtype 
and body site (33‑36), ulceration (36‑38), vascular invasion (39), 
mitotic rate (38) and sentinel lymph node positivity (34,36,40). 
A biological basis for this advantage in female survival has been 
suggested (34,35). A number of factors have been hypothesized 
to contribute to the increased female patient survival, including 
sex‑linked physiological differences in skin, sex hormone levels, 
pregnancy, use of oral contraceptives and hormone replacement 
therapy [reviewed in (41)] and the presence of oxidative stress (42). 
However, the precise biological mechanism underlying this 
phenomenon remains to be determined. In the current study, no 
significant differences between male and female patients in terms 
of age, tumor Breslow thickness, histological subtype, pigment 
and ulceration were observed. No discrepancies in these factors 
were observed when male and female patients were compared 
separately within groups with and without metastasis. However, 
it was demonstrated that melanoma localization differed among 
sexes. A previous study has reported similar results, revealing 
that among various risk factors, only localization is not similarly 
distributed for both sexes (5). In the present study and in the afore‑
mentioned studies, female patients exhibited more melanomas on 
the limbs, whereas male patients had a number of melanomas on 
the trunk (5). According to previous studies, melanomas on the 
trunk exhibit a worse prognosis compared with melanomas on 
the extremities (43‑45). Age is another factor that is often associ‑
ated with a poor prognosis, especially in male patients (46). This 
was not confirmed in the current study, although it was indicated 
that advanced age was associated with a shorter time until the 
onset of metastasis in both sexes.
A major limitation of the current study was acquiring data 
from a large referral center, which may not fully represent the 
Latvian population. However, REUHLOC is the main onco‑
logical hospital in the country, where the majority of patients 
with melanoma are treated. A similar approach to data collection 
has been used previously (47). In addition, patients were not clas‑
sified according to melanoma sub‑stages. The rationale behind 
this decision was as follows. It is important to utilize as much of 
the available information about patients and tumors as possible 
to improve the prediction of metastases. Each conversion of a 
continuous feature, such as Breslow thickness, into a discrete 
characteristic is associated with loss of information and reduces 
the statistical power of models where this feature is included. The 
consequences of collapsing several features into one coarser trait 
are similar. Thus, it is preferable to consider multiple features 
simultaneously in a multivariate model. Using disease stages 
may be beneficial if there were numerous outliers in the data. 
However, such trends were not observed in the present study. The 
type of treatment received by a patient was not incorporated into 
statistical models and is a limitation of the present study. This 
was done as during the study period no novel treatment options 
were available and all patients in the cohort in the present study 
received standard treatments: Patients with stage I and II disease 
were put under observation, stage III melanoma patients mostly 
received interferon alpha (IFN‑α) and for stage IV patients the 
main treatment option was chemotherapy with dacarbazine.
In conclusion, the present study demonstrated that the 
main features associated with the speed of melanoma progres‑
sion and the development of metastasis in Latvia, despite 
the lower 5‑year survival rates, are similar to those reported 
previously and include tumor ulceration, absence of pigment in 
melanoma and tumor Breslow thickness, although the latter is 
not associated with the time at which metastasis is diagnosed. 
The present study also indicated that an additional feature 
associated with melanoma progression is male sex.
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